Your browser doesn't support javascript.
The prevalence of diabetes and thyroid related autoantibodies in Sri Lankan children with type 1 diabetes and their unaffected siblings - The utility of a new screening assay.
Atapattu, Navoda; Amoroso, Marie; Powell, Michael; de Silva, D G Harendra; de Silva, K Shamya H; Furmaniak, Jadwiga; Rees Smith, Bernard; Premawardhana, Lakdasa D.
  • Atapattu N; Endocrinology and Diabetes Unit, Lady Ridgeway Hospital, Colombo, Sri Lanka.
  • Amoroso M; FIRS Laboratories, RSR Ltd., Cardiff, United Kingdom.
  • Powell M; FIRS Laboratories, RSR Ltd., Cardiff, United Kingdom.
  • de Silva DGH; Department of Paediatrics, Lady Ridgeway Hospital and Faculty of Medicine, Colombo, Sri Lanka.
  • de Silva KSH; Department of Paediatrics, Lady Ridgeway Hospital and Faculty of Medicine, Colombo, Sri Lanka.
  • Furmaniak J; FIRS Laboratories, RSR Ltd., Cardiff, United Kingdom.
  • Rees Smith B; FIRS Laboratories, RSR Ltd., Cardiff, United Kingdom.
  • Premawardhana LD; Thyroid Research Group, Cardiff University School of Medicine, Cardiff, United Kingdom.
Front Endocrinol (Lausanne) ; 14: 1028285, 2023.
Artículo en Inglés | MEDLINE | ID: covidwho-2250465
ABSTRACT

Background:

There is limited information about diabetes and thyroid related autoantibodies in children with type 1 diabetes (T1D) or their siblings in Sri Lanka.

Objectives:

To assess in T1D children and their unaffected siblings the prevalence of autoantibodies to (1) glutamic acid decarboxylase (GADA), insulinoma associated antigen-2 (IA-2A) and zinc transporter 8 (ZnT8A) using 3 Screen ICA™ (3-Screen) and individual ELISA assays; (2) insulin (IAA); and (3) thyroid peroxidase (TPOA), thyroglobulin (TgA) and the TSH receptor (TSHRA).

Methods:

We selected - (a) consecutive T1D children, and (b) their unaffected siblings of both sexes, from the T1D Registry at Lady Ridgeway Hospital, Colombo.

Results:

The median age (IQR) of 235 T1D children and 252 unaffected siblings was 11 (8.4, 13.2) and 9 (5.4, 14.9) years respectively, and the duration of T1D was 23 (7, 54) months. (1) T1D children (a) 79.1% were 3-Screen positive; (b) all 3-Screen positives were individual antibody positive (GADA in 74%; IA-2A 31.1%; ZnT8A 38.7%); (c) and were younger (p=0.01 vs 3-Screen negatives); (d) multiple autoantibodies were present in 45.1%; (e) IA-2A (p=0.002) and ZnT8A (p=0.006) prevalence decreased with T1D duration. (f) TPOA and TgA prevalence was higher in T1D children compared to unaffected siblings (28%, p=0.001 and 31%, p=0.004, respectively). (2) Unaffected siblings (a) 6.3% were 3-Screen positive (p=0.001 vs T1D), and 2.4% were positive for IAA; (b) four subjects had two diabetes related autoantibodies, one of whom developed dysglycaemia during follow-up.

Conclusions:

The 3-Screen assay, used for the first time in Sri Lankan T1D children and their siblings as a screening tool, shows a high prevalence of T1D related Abs with a high correlation with individual assays, and is also a helpful tool in screening unaffected siblings for future T1D risk. The higher prevalence of thyroid autoantibodies in T1D children is consistent with polyglandular autoimmunity.
Asunto(s)
Palabras clave

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 1 Tipo de estudio: Estudio de cohorte / Estudio observacional / Estudio pronóstico Tópicos: Variantes Límite: Niño / Femenino / Humanos / Masculino País/Región como asunto: Asia Idioma: Inglés Revista: Front Endocrinol (Lausanne) Año: 2023 Tipo del documento: Artículo País de afiliación: Fendo.2023.1028285

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 1 Tipo de estudio: Estudio de cohorte / Estudio observacional / Estudio pronóstico Tópicos: Variantes Límite: Niño / Femenino / Humanos / Masculino País/Región como asunto: Asia Idioma: Inglés Revista: Front Endocrinol (Lausanne) Año: 2023 Tipo del documento: Artículo País de afiliación: Fendo.2023.1028285